Fresenius Medical Care : Q2 review -solid despite mortality headwind, 2025 guidance reiterated
>Q2 review – In line with expectations - Fresenius Medical Care's Q2 2024 revenues of € 4,766m (-1.2% y-o-y, slightly below vs ODDO BHF/consensus) were supported by organic growth of 2.3% at the group level compared with our forecast of 0.9%. Divestments created a headwind of 400bp and forex created a tailwind of 50bp.Q2 adjusted EBIT of € 433m (+8.0% y-o-y, margin of 8.8%) was in line with expectations. Reported EBIT reached € 425m and was -3%/+4% vs expectation...RegistrarFresenius Medical Care is a kidney dialysis company, operating in both the field of dialysis services and the field of dialysis products for the treatment of end-stage renal disease (ESRD). Co.'s dialysis business is vertically integrated, providing dialysis treatment at dialysis clinics it owns or operates and supplying these clinics with a range of products. In addition, Co. sells dialysis products to other dialysis service providers. In the U.S.A., Co. also provides inpatient dialysis services and other services under contract to hospitals. Co. provides patient services, including renal pharmaceutical products and in the U.S.A., laboratory services.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.